Prothena Biosciences Inc.
Prothena is a clinical-stage biotechnology company with expertise in protein dysregulation and a diverse pipeline of investigational therapies targeting neurodegenerative and rare peripheral amyloid diseases. Committed to developing transformative medicines, Prothena leverages insights into neurological dysfunction and misfolded proteins to create innovative therapeutic solutions. The company collaborates with academic, industry, and business partners to accelerate the development of treatments, aiming to make a significant impact on diseases affecting millions worldwide.
Industries
Nr. of Employees
medium (51-250)
Prothena Biosciences Inc.
South San Francisco, California, United States, North America
Products
Investigational monoclonal antibody program for systemic (AL) amyloidosis — confirmatory late‑phase study
A wholly‑owned investigational monoclonal antibody program in a confirmatory Phase 3 trial designed with a time‑to‑event (all‑cause mortality) primary endpoint under an agreed study design with regulatory authorities.
Investigational subcutaneous anti‑amyloid antibody for early Alzheimer’s disease — early‑phase study
An investigational anti‑amyloid antibody evaluated in early‑phase clinical trials with a subcutaneous, once‑monthly dosing regimen intended to reduce treatment burden for patients.
Partnered anti‑amyloid program for ATTR amyloidosis with cardiomyopathy — mid‑phase study
A partnered anti‑amyloid antibody program being evaluated in a Phase 2 signal‑detection trial for transthyretin amyloid cardiomyopathy.
Partnered anti‑tau antibody programs for neurodegenerative disease
Partnered antibody programs targeting tau biology for the treatment or prevention of Alzheimer’s disease and related neurodegenerative disorders, advancing through mid‑phase clinical development.
Investigational monoclonal antibody program for systemic (AL) amyloidosis — confirmatory late‑phase study
A wholly‑owned investigational monoclonal antibody program in a confirmatory Phase 3 trial designed with a time‑to‑event (all‑cause mortality) primary endpoint under an agreed study design with regulatory authorities.
Investigational subcutaneous anti‑amyloid antibody for early Alzheimer’s disease — early‑phase study
An investigational anti‑amyloid antibody evaluated in early‑phase clinical trials with a subcutaneous, once‑monthly dosing regimen intended to reduce treatment burden for patients.
Partnered anti‑amyloid program for ATTR amyloidosis with cardiomyopathy — mid‑phase study
A partnered anti‑amyloid antibody program being evaluated in a Phase 2 signal‑detection trial for transthyretin amyloid cardiomyopathy.
Partnered anti‑tau antibody programs for neurodegenerative disease
Partnered antibody programs targeting tau biology for the treatment or prevention of Alzheimer’s disease and related neurodegenerative disorders, advancing through mid‑phase clinical development.
Services
Collaborative research and co‑development partnerships
Strategic collaborations with biotech, pharmaceutical and academic partners, including engagement with key opinion leaders and patient associations, to advance discovery, preclinical development and clinical programs.
Collaborative research and co‑development partnerships
Strategic collaborations with biotech, pharmaceutical and academic partners, including engagement with key opinion leaders and patient associations, to advance discovery, preclinical development and clinical programs.
Expertise Areas
- Antibody discovery and engineering
- Protein misfolding and amyloid biology
- Translational neuroscience research
- Clinical trial design and operations (Phase 1–3)
Key Technologies
- Monoclonal antibody therapeutics
- Subcutaneous biologic formulation
- Biomarker‑driven clinical development
- Clinical study design methodologies